Angiotensin II receptor blocker irbesartan attenuates cardiac dysfunction induced by myocardial infarction in the presence of renal failure View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-12-10

AUTHORS

Ryo Watanabe, Jun-ichi Suzuki, Kouji Wakayama, Hidetoshi Kumagai, Yuichi Ikeda, Hiroshi Akazawa, Issei Komuro, Mitsuaki Isobe

ABSTRACT

The activity of the renin–angiotensin system is known to be a key factor in the pathophysiology of heart failure and renal failure. Irbesartan, an angiotensin II receptor blocker, has non-hemodynamic cardiovascular and renal protective effects. However, the effect of irbesartan on heart failure complicated by renal failure has not yet been elucidated. Thus the purpose of this study was to evaluate the effect of irbesartan on the pathophysiology of cardiorenal syndrome in a rat model. Subtotal nephrectomy (NTX) was performed in rats was using a two-step surgical procedure. Twenty-eight days after NTX, myocardial infarction (MI) was induced by ligation of the left anterior descending coronary artery. The animals were orally administered vehicle or irbesartan (10 mg kg−1 day−1) after NTX. The hearts were harvested 28 days after MI. MI with NTX model rats showed an impaired post-MI survival rate and enhanced cardiac inflammation in comparison to MI without NTX rats. Although irbesartan treatment did not improve the survival rate, it suppressed cardiac inflammation, left ventricular function decline, cardiac fibrosis, hypertrophy of cardiomyocytes and renal fibrosis in MI with NTX rats. Moreover, increases in protein expression levels related to oxidative stress and inflammation (NADPH oxidase 4, phospho-nuclear factor-κB and phospho-c-Jun) observed in the hearts of non-treated MI with NTX rats were attenuated by irbesartan treatment. These effects of irbesartan treatment were independent of blood pressure. We conclude that irbesartan has a cardioprotective effect after MI when renal dysfunction is present. More... »

PAGES

237-244

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/hr.2015.141

DOI

http://dx.doi.org/10.1038/hr.2015.141

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1036733537

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26657004


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiotensin II Type 1 Receptor Blockers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biphenyl Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Irbesartan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myocardial Infarction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myocardium", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "NADPH Oxidase 4", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "NADPH Oxidases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "NF-kappa B", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phosphorylation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-jun", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats, Sprague-Dawley", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Renal Insufficiency", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Renin-Angiotensin System", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tetrazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ventricular Dysfunction, Left", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.265073.5", 
          "name": [
            "Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Watanabe", 
        "givenName": "Ryo", 
        "id": "sg:person.0664160400.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664160400.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Advanced Clinical Science and Therapeutics, The University of Tokyo, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.26999.3d", 
          "name": [
            "Department of Advanced Clinical Science and Therapeutics, The University of Tokyo, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Suzuki", 
        "givenName": "Jun-ichi", 
        "id": "sg:person.0772072503.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772072503.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Advanced Clinical Science and Therapeutics, The University of Tokyo, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.26999.3d", 
          "name": [
            "Department of Advanced Clinical Science and Therapeutics, The University of Tokyo, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wakayama", 
        "givenName": "Kouji", 
        "id": "sg:person.0714750211.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714750211.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Advanced Clinical Science and Therapeutics, The University of Tokyo, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.26999.3d", 
          "name": [
            "Department of Advanced Clinical Science and Therapeutics, The University of Tokyo, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kumagai", 
        "givenName": "Hidetoshi", 
        "id": "sg:person.0736053075.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736053075.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.26999.3d", 
          "name": [
            "Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ikeda", 
        "givenName": "Yuichi", 
        "id": "sg:person.012757402652.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012757402652.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.26999.3d", 
          "name": [
            "Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Akazawa", 
        "givenName": "Hiroshi", 
        "id": "sg:person.01150350762.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150350762.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.26999.3d", 
          "name": [
            "Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Komuro", 
        "givenName": "Issei", 
        "id": "sg:person.01012024207.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012024207.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.265073.5", 
          "name": [
            "Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Isobe", 
        "givenName": "Mitsuaki", 
        "id": "sg:person.01266743300.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266743300.99"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.2165/00003495-200464090-00011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047278519", 
          "https://doi.org/10.2165/00003495-200464090-00011"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/hr.2013.119", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052959530", 
          "https://doi.org/10.1038/hr.2013.119"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/labinvest.2012.136", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030741051", 
          "https://doi.org/10.1038/labinvest.2012.136"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11033-014-3685-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051107119", 
          "https://doi.org/10.1007/s11033-014-3685-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/hr.2010.135", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003902715", 
          "https://doi.org/10.1038/hr.2010.135"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/labinvest.2011.45", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024905795", 
          "https://doi.org/10.1038/labinvest.2011.45"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00395-011-0242-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007035389", 
          "https://doi.org/10.1007/s00395-011-0242-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/hr.2012.223", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020049647", 
          "https://doi.org/10.1038/hr.2012.223"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/hr.2014.136", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034426067", 
          "https://doi.org/10.1038/hr.2014.136"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-12-10", 
    "datePublishedReg": "2015-12-10", 
    "description": "The activity of the renin\u2013angiotensin system is known to be a key factor in the pathophysiology of heart failure and renal failure. Irbesartan, an angiotensin II receptor blocker, has non-hemodynamic cardiovascular and renal protective effects. However, the effect of irbesartan on heart failure complicated by renal failure has not yet been elucidated. Thus the purpose of this study was to evaluate the effect of irbesartan on the pathophysiology of cardiorenal syndrome in a rat model. Subtotal nephrectomy (NTX) was performed in rats was using a two-step surgical procedure. Twenty-eight days after NTX, myocardial infarction (MI) was induced by ligation of the left anterior descending coronary artery. The animals were orally administered vehicle or irbesartan (10\u2009mg\u2009kg\u22121\u2009day\u22121) after NTX. The hearts were harvested 28 days after MI. MI with NTX model rats showed an impaired post-MI survival rate and enhanced cardiac inflammation in comparison to MI without NTX rats. Although irbesartan treatment did not improve the survival rate, it suppressed cardiac inflammation, left ventricular function decline, cardiac fibrosis, hypertrophy of cardiomyocytes and renal fibrosis in MI with NTX rats. Moreover, increases in protein expression levels related to oxidative stress and inflammation (NADPH oxidase 4, phospho-nuclear factor-\u03baB and phospho-c-Jun) observed in the hearts of non-treated MI with NTX rats were attenuated by irbesartan treatment. These effects of irbesartan treatment were independent of blood pressure. We conclude that irbesartan has a cardioprotective effect after MI when renal dysfunction is present.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/hr.2015.141", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.5862646", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.6139743", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.6121593", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.5863147", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.5924270", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.5917705", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1313717", 
        "issn": [
          "0916-9636", 
          "1348-4214"
        ], 
        "name": "Hypertension Research", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "39"
      }
    ], 
    "keywords": [
      "effects of irbesartan", 
      "myocardial infarction", 
      "NTX rats", 
      "irbesartan treatment", 
      "renal failure", 
      "heart failure", 
      "cardiac inflammation", 
      "angiotensin II receptor blocker irbesartan", 
      "survival rate", 
      "angiotensin II receptor blockers", 
      "renin-angiotensin system", 
      "two-step surgical procedure", 
      "renal protective effects", 
      "receptor blocker irbesartan", 
      "hypertrophy of cardiomyocytes", 
      "cardiorenal syndrome", 
      "receptor blockers", 
      "renal dysfunction", 
      "blocker irbesartan", 
      "blood pressure", 
      "subtotal nephrectomy", 
      "protein expression levels", 
      "cardiac dysfunction", 
      "function decline", 
      "coronary artery", 
      "renal fibrosis", 
      "cardioprotective effects", 
      "model rats", 
      "rat model", 
      "cardiac fibrosis", 
      "protective effect", 
      "surgical procedures", 
      "rats", 
      "irbesartan", 
      "inflammation", 
      "oxidative stress", 
      "NTX", 
      "infarction", 
      "pathophysiology", 
      "dysfunction", 
      "fibrosis", 
      "expression levels", 
      "treatment", 
      "failure", 
      "heart", 
      "days", 
      "nephrectomy", 
      "artery", 
      "syndrome", 
      "hypertrophy", 
      "blockers", 
      "effect", 
      "ligation", 
      "cardiomyocytes", 
      "animals", 
      "rate", 
      "factors", 
      "decline", 
      "levels", 
      "activity", 
      "study", 
      "increase", 
      "pressure", 
      "procedure", 
      "presence", 
      "purpose", 
      "key factor", 
      "stress", 
      "comparison", 
      "model", 
      "vehicle", 
      "system", 
      "II receptor blocker", 
      "NTX model rats", 
      "MI survival rate", 
      "ventricular function decline", 
      "non-treated MI", 
      "II receptor blocker irbesartan"
    ], 
    "name": "Angiotensin II receptor blocker irbesartan attenuates cardiac dysfunction induced by myocardial infarction in the presence of renal failure", 
    "pagination": "237-244", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1036733537"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/hr.2015.141"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26657004"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/hr.2015.141", 
      "https://app.dimensions.ai/details/publication/pub.1036733537"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:32", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_655.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/hr.2015.141"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/hr.2015.141'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/hr.2015.141'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/hr.2015.141'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/hr.2015.141'


 

This table displays all metadata directly associated to this object as RDF triples.

318 TRIPLES      22 PREDICATES      132 URIs      115 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/hr.2015.141 schema:about N1f6a1952ba8c4fd4b412ed74691e1136
2 N3eb8fcb62562444bbad88d6ef9cb9417
3 N3f2ff7e99f8448aca41166576c278415
4 N40a708192ee146a192929b783029b9a5
5 N47dd4833f1514ba1a804dbcd600cd959
6 N6a0e13dd9794413ab0a86d2985637681
7 N75fdbe7bf6414575a1fbef3bc27930c8
8 N7ae3ee05cc6244e1819ec399f7207ca3
9 N82a76edbfee74ae7a8de6f55bc6ee01f
10 N8638d5287ce547a2abca3d95f7ca7577
11 Nacdb895f2fa04bd189e072a7dd7b5424
12 Nd542a9a56f124684a83aa35b64337ef0
13 Nddbf1de9efc449f89290a672e51a378c
14 Ne5b308da48eb4a4393f6da9599dcf093
15 Nf466ae7f17754057a0d18594b1ed0b68
16 Nf4add42ea30643b4ba26ee198f06fb91
17 Nfb0233d8ed1a41b89f62cc2230cd0e66
18 Nfbc713752d7f45ee8fd0f5b225adcb36
19 Nfc5d9e56101b4c8885c52f4324cf99c9
20 anzsrc-for:11
21 anzsrc-for:1102
22 schema:author Nea11b8a38fe0496fb69db4e611309023
23 schema:citation sg:pub.10.1007/s00395-011-0242-4
24 sg:pub.10.1007/s11033-014-3685-5
25 sg:pub.10.1038/hr.2010.135
26 sg:pub.10.1038/hr.2012.223
27 sg:pub.10.1038/hr.2013.119
28 sg:pub.10.1038/hr.2014.136
29 sg:pub.10.1038/labinvest.2011.45
30 sg:pub.10.1038/labinvest.2012.136
31 sg:pub.10.2165/00003495-200464090-00011
32 schema:datePublished 2015-12-10
33 schema:datePublishedReg 2015-12-10
34 schema:description The activity of the renin–angiotensin system is known to be a key factor in the pathophysiology of heart failure and renal failure. Irbesartan, an angiotensin II receptor blocker, has non-hemodynamic cardiovascular and renal protective effects. However, the effect of irbesartan on heart failure complicated by renal failure has not yet been elucidated. Thus the purpose of this study was to evaluate the effect of irbesartan on the pathophysiology of cardiorenal syndrome in a rat model. Subtotal nephrectomy (NTX) was performed in rats was using a two-step surgical procedure. Twenty-eight days after NTX, myocardial infarction (MI) was induced by ligation of the left anterior descending coronary artery. The animals were orally administered vehicle or irbesartan (10 mg kg−1 day−1) after NTX. The hearts were harvested 28 days after MI. MI with NTX model rats showed an impaired post-MI survival rate and enhanced cardiac inflammation in comparison to MI without NTX rats. Although irbesartan treatment did not improve the survival rate, it suppressed cardiac inflammation, left ventricular function decline, cardiac fibrosis, hypertrophy of cardiomyocytes and renal fibrosis in MI with NTX rats. Moreover, increases in protein expression levels related to oxidative stress and inflammation (NADPH oxidase 4, phospho-nuclear factor-κB and phospho-c-Jun) observed in the hearts of non-treated MI with NTX rats were attenuated by irbesartan treatment. These effects of irbesartan treatment were independent of blood pressure. We conclude that irbesartan has a cardioprotective effect after MI when renal dysfunction is present.
35 schema:genre article
36 schema:inLanguage en
37 schema:isAccessibleForFree true
38 schema:isPartOf N06d8ebeecf5f4fd9864c5fe4f4d6968f
39 N593639db4b6e43148728fb5845093ec2
40 sg:journal.1313717
41 schema:keywords II receptor blocker
42 II receptor blocker irbesartan
43 MI survival rate
44 NTX
45 NTX model rats
46 NTX rats
47 activity
48 angiotensin II receptor blocker irbesartan
49 angiotensin II receptor blockers
50 animals
51 artery
52 blocker irbesartan
53 blockers
54 blood pressure
55 cardiac dysfunction
56 cardiac fibrosis
57 cardiac inflammation
58 cardiomyocytes
59 cardioprotective effects
60 cardiorenal syndrome
61 comparison
62 coronary artery
63 days
64 decline
65 dysfunction
66 effect
67 effects of irbesartan
68 expression levels
69 factors
70 failure
71 fibrosis
72 function decline
73 heart
74 heart failure
75 hypertrophy
76 hypertrophy of cardiomyocytes
77 increase
78 infarction
79 inflammation
80 irbesartan
81 irbesartan treatment
82 key factor
83 levels
84 ligation
85 model
86 model rats
87 myocardial infarction
88 nephrectomy
89 non-treated MI
90 oxidative stress
91 pathophysiology
92 presence
93 pressure
94 procedure
95 protective effect
96 protein expression levels
97 purpose
98 rat model
99 rate
100 rats
101 receptor blocker irbesartan
102 receptor blockers
103 renal dysfunction
104 renal failure
105 renal fibrosis
106 renal protective effects
107 renin-angiotensin system
108 stress
109 study
110 subtotal nephrectomy
111 surgical procedures
112 survival rate
113 syndrome
114 system
115 treatment
116 two-step surgical procedure
117 vehicle
118 ventricular function decline
119 schema:name Angiotensin II receptor blocker irbesartan attenuates cardiac dysfunction induced by myocardial infarction in the presence of renal failure
120 schema:pagination 237-244
121 schema:productId N17be3587c7764d1ab17ad6202eb8a304
122 N9d22b8e37b6d42e1a9ddb4d1029f50db
123 Nf18c4249d51547d5b3cd4f74931d51b2
124 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036733537
125 https://doi.org/10.1038/hr.2015.141
126 schema:sdDatePublished 2021-12-01T19:32
127 schema:sdLicense https://scigraph.springernature.com/explorer/license/
128 schema:sdPublisher N599292d741114a86842d944bd6824098
129 schema:url https://doi.org/10.1038/hr.2015.141
130 sgo:license sg:explorer/license/
131 sgo:sdDataset articles
132 rdf:type schema:ScholarlyArticle
133 N06d8ebeecf5f4fd9864c5fe4f4d6968f schema:volumeNumber 39
134 rdf:type schema:PublicationVolume
135 N08c9da7e59e64541a78c5144911fe799 rdf:first sg:person.01266743300.99
136 rdf:rest rdf:nil
137 N17be3587c7764d1ab17ad6202eb8a304 schema:name dimensions_id
138 schema:value pub.1036733537
139 rdf:type schema:PropertyValue
140 N1f6a1952ba8c4fd4b412ed74691e1136 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Ventricular Dysfunction, Left
142 rdf:type schema:DefinedTerm
143 N3abe5df0c9c444d38dbc0ae5357b2088 rdf:first sg:person.01012024207.33
144 rdf:rest N08c9da7e59e64541a78c5144911fe799
145 N3eb8fcb62562444bbad88d6ef9cb9417 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Animals
147 rdf:type schema:DefinedTerm
148 N3f2ff7e99f8448aca41166576c278415 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Angiotensin II Type 1 Receptor Blockers
150 rdf:type schema:DefinedTerm
151 N40a708192ee146a192929b783029b9a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Myocardial Infarction
153 rdf:type schema:DefinedTerm
154 N47dd4833f1514ba1a804dbcd600cd959 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Rats, Sprague-Dawley
156 rdf:type schema:DefinedTerm
157 N4d3d331e085a4961a807c180527ad188 rdf:first sg:person.0772072503.18
158 rdf:rest N9ce579c17a854aabb0a8ecc0b98a739e
159 N593639db4b6e43148728fb5845093ec2 schema:issueNumber 4
160 rdf:type schema:PublicationIssue
161 N599292d741114a86842d944bd6824098 schema:name Springer Nature - SN SciGraph project
162 rdf:type schema:Organization
163 N6118c546ae324358861ed0585fc6bc17 rdf:first sg:person.0736053075.51
164 rdf:rest N8f4363c2b21643b5b97ddb9a3f9f84ad
165 N6a0e13dd9794413ab0a86d2985637681 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name NF-kappa B
167 rdf:type schema:DefinedTerm
168 N75fdbe7bf6414575a1fbef3bc27930c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Renal Insufficiency
170 rdf:type schema:DefinedTerm
171 N7ae3ee05cc6244e1819ec399f7207ca3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Myocardium
173 rdf:type schema:DefinedTerm
174 N82a76edbfee74ae7a8de6f55bc6ee01f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Proto-Oncogene Proteins c-jun
176 rdf:type schema:DefinedTerm
177 N8638d5287ce547a2abca3d95f7ca7577 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Renin-Angiotensin System
179 rdf:type schema:DefinedTerm
180 N8f4363c2b21643b5b97ddb9a3f9f84ad rdf:first sg:person.012757402652.04
181 rdf:rest Nc10fc26d1163457ab1341705106f4b8e
182 N9ce579c17a854aabb0a8ecc0b98a739e rdf:first sg:person.0714750211.11
183 rdf:rest N6118c546ae324358861ed0585fc6bc17
184 N9d22b8e37b6d42e1a9ddb4d1029f50db schema:name doi
185 schema:value 10.1038/hr.2015.141
186 rdf:type schema:PropertyValue
187 Nacdb895f2fa04bd189e072a7dd7b5424 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name NADPH Oxidases
189 rdf:type schema:DefinedTerm
190 Nc10fc26d1163457ab1341705106f4b8e rdf:first sg:person.01150350762.93
191 rdf:rest N3abe5df0c9c444d38dbc0ae5357b2088
192 Nd542a9a56f124684a83aa35b64337ef0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Heart
194 rdf:type schema:DefinedTerm
195 Nddbf1de9efc449f89290a672e51a378c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Biphenyl Compounds
197 rdf:type schema:DefinedTerm
198 Ne5b308da48eb4a4393f6da9599dcf093 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Irbesartan
200 rdf:type schema:DefinedTerm
201 Nea11b8a38fe0496fb69db4e611309023 rdf:first sg:person.0664160400.92
202 rdf:rest N4d3d331e085a4961a807c180527ad188
203 Nf18c4249d51547d5b3cd4f74931d51b2 schema:name pubmed_id
204 schema:value 26657004
205 rdf:type schema:PropertyValue
206 Nf466ae7f17754057a0d18594b1ed0b68 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Tetrazoles
208 rdf:type schema:DefinedTerm
209 Nf4add42ea30643b4ba26ee198f06fb91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
210 schema:name Male
211 rdf:type schema:DefinedTerm
212 Nfb0233d8ed1a41b89f62cc2230cd0e66 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Rats
214 rdf:type schema:DefinedTerm
215 Nfbc713752d7f45ee8fd0f5b225adcb36 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
216 schema:name Phosphorylation
217 rdf:type schema:DefinedTerm
218 Nfc5d9e56101b4c8885c52f4324cf99c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
219 schema:name NADPH Oxidase 4
220 rdf:type schema:DefinedTerm
221 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
222 schema:name Medical and Health Sciences
223 rdf:type schema:DefinedTerm
224 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
225 schema:name Cardiorespiratory Medicine and Haematology
226 rdf:type schema:DefinedTerm
227 sg:grant.5862646 http://pending.schema.org/fundedItem sg:pub.10.1038/hr.2015.141
228 rdf:type schema:MonetaryGrant
229 sg:grant.5863147 http://pending.schema.org/fundedItem sg:pub.10.1038/hr.2015.141
230 rdf:type schema:MonetaryGrant
231 sg:grant.5917705 http://pending.schema.org/fundedItem sg:pub.10.1038/hr.2015.141
232 rdf:type schema:MonetaryGrant
233 sg:grant.5924270 http://pending.schema.org/fundedItem sg:pub.10.1038/hr.2015.141
234 rdf:type schema:MonetaryGrant
235 sg:grant.6121593 http://pending.schema.org/fundedItem sg:pub.10.1038/hr.2015.141
236 rdf:type schema:MonetaryGrant
237 sg:grant.6139743 http://pending.schema.org/fundedItem sg:pub.10.1038/hr.2015.141
238 rdf:type schema:MonetaryGrant
239 sg:journal.1313717 schema:issn 0916-9636
240 1348-4214
241 schema:name Hypertension Research
242 schema:publisher Springer Nature
243 rdf:type schema:Periodical
244 sg:person.01012024207.33 schema:affiliation grid-institutes:grid.26999.3d
245 schema:familyName Komuro
246 schema:givenName Issei
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012024207.33
248 rdf:type schema:Person
249 sg:person.01150350762.93 schema:affiliation grid-institutes:grid.26999.3d
250 schema:familyName Akazawa
251 schema:givenName Hiroshi
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150350762.93
253 rdf:type schema:Person
254 sg:person.01266743300.99 schema:affiliation grid-institutes:grid.265073.5
255 schema:familyName Isobe
256 schema:givenName Mitsuaki
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266743300.99
258 rdf:type schema:Person
259 sg:person.012757402652.04 schema:affiliation grid-institutes:grid.26999.3d
260 schema:familyName Ikeda
261 schema:givenName Yuichi
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012757402652.04
263 rdf:type schema:Person
264 sg:person.0664160400.92 schema:affiliation grid-institutes:grid.265073.5
265 schema:familyName Watanabe
266 schema:givenName Ryo
267 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664160400.92
268 rdf:type schema:Person
269 sg:person.0714750211.11 schema:affiliation grid-institutes:grid.26999.3d
270 schema:familyName Wakayama
271 schema:givenName Kouji
272 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714750211.11
273 rdf:type schema:Person
274 sg:person.0736053075.51 schema:affiliation grid-institutes:grid.26999.3d
275 schema:familyName Kumagai
276 schema:givenName Hidetoshi
277 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736053075.51
278 rdf:type schema:Person
279 sg:person.0772072503.18 schema:affiliation grid-institutes:grid.26999.3d
280 schema:familyName Suzuki
281 schema:givenName Jun-ichi
282 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772072503.18
283 rdf:type schema:Person
284 sg:pub.10.1007/s00395-011-0242-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007035389
285 https://doi.org/10.1007/s00395-011-0242-4
286 rdf:type schema:CreativeWork
287 sg:pub.10.1007/s11033-014-3685-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051107119
288 https://doi.org/10.1007/s11033-014-3685-5
289 rdf:type schema:CreativeWork
290 sg:pub.10.1038/hr.2010.135 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003902715
291 https://doi.org/10.1038/hr.2010.135
292 rdf:type schema:CreativeWork
293 sg:pub.10.1038/hr.2012.223 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020049647
294 https://doi.org/10.1038/hr.2012.223
295 rdf:type schema:CreativeWork
296 sg:pub.10.1038/hr.2013.119 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052959530
297 https://doi.org/10.1038/hr.2013.119
298 rdf:type schema:CreativeWork
299 sg:pub.10.1038/hr.2014.136 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034426067
300 https://doi.org/10.1038/hr.2014.136
301 rdf:type schema:CreativeWork
302 sg:pub.10.1038/labinvest.2011.45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024905795
303 https://doi.org/10.1038/labinvest.2011.45
304 rdf:type schema:CreativeWork
305 sg:pub.10.1038/labinvest.2012.136 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030741051
306 https://doi.org/10.1038/labinvest.2012.136
307 rdf:type schema:CreativeWork
308 sg:pub.10.2165/00003495-200464090-00011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047278519
309 https://doi.org/10.2165/00003495-200464090-00011
310 rdf:type schema:CreativeWork
311 grid-institutes:grid.265073.5 schema:alternateName Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan
312 schema:name Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan
313 rdf:type schema:Organization
314 grid-institutes:grid.26999.3d schema:alternateName Department of Advanced Clinical Science and Therapeutics, The University of Tokyo, Tokyo, Japan
315 Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan
316 schema:name Department of Advanced Clinical Science and Therapeutics, The University of Tokyo, Tokyo, Japan
317 Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan
318 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...